Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part B

Neurobiology of the Gilles De La Tourette Syndrome and Chronic Tics: Part B

Cavanna, Andrea E.; Lavoie, Marc E.

Elsevier Science & Technology

09/2022

400

Dura

Inglês

9780323910361

15 a 20 dias

450

Descrição não disponível.
Preface Marc E. Lavoie and Andrea E. Cavanna 1. The genetic basis of Gilles de la Tourette syndrome Sarah B. Abdallah, Evan Realbuto, Mary Oluwatosin Kaka, Kelly Yang, Apostolia Topaloudi, Peristera Paschou, Jeremiah M. Scharf and Thomas V. Fernandez 2. Studying the pathophysiology of tic disorders in animal models Christopher Pittenger 3. The neural-immune crosstalk in Tourette syndrome: From immunobiology to epistemology Yasamin Mahjoub, Davide Martino and Andrea E. Cavanna 4. Functional connectivity in the Gilles de la Tourette syndrome Matthew Feigelis and Deanna J. Greene 5. Perception-action integration in Gilles de la Tourette syndrome Theresa Paulus, Christian Beste and Alexander Muenchau 6. The pharmacological treatment of Tourette syndrome Jose Fidel Baizabal-Carvallo and Joseph Jankovic 7. Ecopipam: A D1 receptor antagonist for the treatment of Tourette syndrome Richard E. Chipkin, Donald L. Gilbert and Atul Mahableshwarkar 8. Atypical antipsychotics for treatment of Tourette syndrome Vamsi K. Kalari, Peter E. Morrison and Cathy L. Budman 9. Alpha agonists for the treatment of Tourette syndrome Nick Cothros and Tamara Pringsheim 10. Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome Natalia Szejko and Kirsten Mueller-Vahl 11. Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid and steroid-based tools Marco Bortolato and Roberto Cadeddu 12. Non-invasive brain stimulation for the treatment of Tourette's syndrome Sneha Chenji, Kayla D. Stone and Frank P. MacMaster 13. Entrainment of movement-related brain oscillations to improve symptoms in Tourette syndrome Mairi Houlgreave, Barbara Morera Maiquez, Katherine Dyke, Georgina Jackson and Stephen Jackson 14. Network oscillatory activity in chronic tics and Tourette syndrome Joohi Jimenez-Shahed
2-AG; Action file; Adolescence; Allergies; Alpha-2 adrenergic agonists; Animal models; Antagonist; Antipsychotics; Atypical antipsychotics; Basal ganglia; Beta; Brain networks; Cannabinoids; Cannabis; Cannabis based medicine; Child and adolescent psychiatry; Childhood; Clinical trial; Clonidine; Copy-number variation; Cortex; D1 receptor; Deep brain stimulation; Dopamine; Dopamine depleters; Dronabinol; Ecopipam; EEG; Endocannabinoid modulator; Endocannabinoid system; Entrainment; Epistemology; Event file; Exome sequencing; fMRI; Functional connectivity; Genetics; Genome-wide association; Genomics; Gilles de la Tourette syndrome; Globus pallidus interna; Guanfacine; Heritability; Immunity; Infections; Interneurons; Local field potentials; Median nerve stimulation; MEG; Motor; Mu-alpha; Nabiximols; Neuroactive steroids; Non-invasive brain stimulation; Object file; Oscillation; Pathway analysis; Pediatric; Pediatric neurology; Perception-action integration; Pharmacological therapy; Polygenic risk; Resting state; Second generation antipsychotics; Sensorimotor; Sensorimotor processing; Supplementary motor area; Thalamus; THC; Theory of Event Coding; Tic disorders; Tics; Topiramate; Tourette; Tourette syndrome; Tourette's syndrome; Transcranial direct current stimulation; Transcranial magnetic stimulation